0812 ET - Jazz Pharmaceuticals' $935 million deal to buy Chimerix carries a potential quick payoff in the form of an FDA priority review voucher. Chimerix's dordaviprone, which is under FDA review with an August 18 target action date, may be eligible for one of the vouchers, which the agency awards upon approval of drugs previously granted rare-pediatric-disease designation. The vouchers can be used to obtain priority review for another drug or sold to other companies, and a trio of recent deals has seen vouchers change hands at $150 million apiece. Chimerix rockets 70% premarket. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 08:12 ET (13:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。